APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)
Part of paid clinical trials in Nashville, Tennessee.
- Sponsor
- Vanderbilt University Medical Center
- Study ID
- NCT07492134
- Phase
- PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Acute Uncomplicated Diverticulitis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 90 Years
- Healthy Volunteers
- Not accepted
Interventions
- Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet — DRUGamoxicillin-clavulanate:1 tablet \[875 mg amoxicillin; 125 mg clavulanic acid\] every 8 hours
- Placebo — DRUGA placebo matching the antibiotic arm's treatment regimen will be administered for 10 days
- Metronidazole — DRUGmetronidazole: 500 mg every 12 hours
- Cefuroxime — DRUGcefuroxime: 500 mg every 12 hours
Study Details
The goal of this clinical trial is to determine whether antibiotics improve recovery from acute uncomplicated diverticulitis (AUD) in racially and ethnically diverse United States clinical practice. The main questions it seeks to answer are: * What is the feasibility for completing a subsequent definitive efficacy trial of antibiotics vs. placebo to treat AUD? * What are the needs for successful recruitment of racial and ethnic subgroups? * What are the effects of a placebo compared to antibiotics for AUD on a range of key patient-centric efficacy and safety endpoints? * How do such effects differ by race and ethnicity? Researchers will compare a placebo to antibiotics to see if AUD can be treated without using antibiotics. Participants will: * Take two antibiotics or a matching placebo every day for 10 days * Receive analgesia, gastric protection, diet modifications, and a follow-up * Submit daily photos of pills to the study team to verify adherence
Key Dates
- Start date
- Apr 1, 2026
- Status verified
- Apr 2026
- Primary completion
- Apr 1, 2028
- Completion
- Oct 1, 2028
Study Design
- Enrollment
- 100 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: AntibioticThe primary antibiotic choice will be amoxicillin-clavulanate (1 tablet \[875 mg amoxicillin; 125 mg clavulanic acid\] every 8 hours). If the subject has an allergy or contraindication to the primary antibiotic, we will administer cefuroxime \[500 mg\] every 12 hours plus metronidazole \[500 mg\] every 12 hours.
- Experimental: PlaceboA placebo matching the antibiotic arm's treatment regimen will be administered for 10 days
Primary Outcome Measure
Recruitment Rate [ Time Frame: From enrollment through study completion, an average of 2 years. ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Vanderbilt University Medical Center Emergency Department | Nashville | Tennessee | 37235 |
Find similar trials in Nashville, TN
Related Studies
- Non-antibiotic Management in Acute Uncomplicated DiverticulitisPHASE4 · Not Yet Recruiting · Montefiore Medical Center · The Bronx, New York